Results 41 to 50 of about 115,969,812 (153)

Neurofilament light is a treatment‐responsive biomarker in CLN2 disease

open access: yesAnnals of Clinical and Translational Neurology, 2019
Objective Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare, progressive, fatal neurodegenerative pediatric disorder resulting from deficiencies of the lysosomal enzyme tripeptidyl peptidase 1 that are caused by mutations in TPP1 ...
Yuanbin Ru   +12 more
doaj   +1 more source

Mutations in classical late infantile neuronal ceroid lipofuscinosis disrupt transport of tripeptidyl-peptidase I to lysosomes [PDF]

open access: yes, 2004
Classical late infantile neuronal ceroid lipofuscinosis is an autosomal recessive disease caused by mutations in the CLN2 gene resulting in functional defects of the gene product tripeptidyl-peptidase I.
Isbrandt, D.   +9 more
core   +1 more source

Chronic Enzyme Replacement to the Brain of a Late Infantile Neuronal Ceroid Lipofuscinosis Mouse Has Differential Effects on Phenotypes of Disease

open access: yesMolecular Therapy: Methods & Clinical Development, 2017
Late infantile neuronal ceroid lipofuscinosis (LINCL) is a fatal inherited neurodegenerative disease caused by loss of lysosomal protease tripeptidyl peptidase 1 (TPP1).
Jennifer A. Wiseman   +7 more
doaj   +1 more source

Processing of Two Latent Membrane Protein 1 MHC Class I Epitopes Requires Tripeptidyl Peptidase II Involvement [PDF]

open access: yesThe Journal of Immunology, 2009
Abstract The EBV Ag latent membrane protein 1 (LMP1) has been described as a potential target for T cell immunotherapy in EBV-related malignancies. However, only a few CD8+ T cell epitopes are known, and the benefit of LMP1-specific T cell immunotherapy has not yet been proven.
Jan, Diekmann   +9 more
openaire   +2 more sources

A tailored mouse model of CLN2 disease: A nonsense mutant for testing personalized therapies. [PDF]

open access: yesPLoS ONE, 2017
The Neuronal Ceroid Lipofuscinoses (NCLs), also known as Batten disease, result from mutations in over a dozen genes. Although, adults are susceptible, the NCLs are frequently classified as pediatric neurodegenerative diseases due to their greater ...
Ryan D Geraets   +7 more
doaj   +1 more source

Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease

open access: yesClinical and Translational Science, 2021
Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is an ultra‐rare pediatric neurodegenerative disorder characterized by deficiency of the lysosomal enzyme tripeptidyl peptidase‐1 (TPP1).
Kevin Hammon   +7 more
doaj   +1 more source

Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration

open access: yesClinical and Translational Science, 2021
Cerliponase alfa is recombinant human tripeptidyl peptidase 1 (TPP1) delivered by i.c.v. infusion for CLN2, a pediatric neurodegenerative disease caused by deficiency in lysosomal enzyme TPP1.
Aryun Kim   +12 more
doaj   +1 more source

Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I1 [PDF]

open access: yesFEBS Letters, 1999
Tripeptidyl peptidase I (TPP‐I) is a lysosomal enzyme that cleaves tripeptides from the N‐terminus of polypeptides. A comparison of TPP‐I amino acid sequences with sequences derived from an EST database suggested that TPP‐I is identical to a pepstatin‐insensitive carboxyl proteinase of unknown specificity which is mutated in classical late infantile ...
David J Vines, Michael J Warburton
openaire   +1 more source

Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment [version 2; peer review: 2 approved]

open access: yesF1000Research, 2022
Classic late infantile neuronal ceroid lipofuscinosis (CLN2 disease) is caused by a deficiency of tripeptidyl-peptidase-1. In 2017, the first CLN2 enzyme replacement therapy (ERT) cerliponase alfa (Brineura) was approved by the FDA and EMA.
Wendy E. Heywood   +11 more
doaj   +1 more source

Tripeptidyl Peptidase II Mediates Levels of Nuclear Phosphorylated ERK1 and ERK2. [PDF]

open access: yes, 2015
Tripeptidyl peptidase II (TPP2) is a serine peptidase involved in various biological processes, including antigen processing, cell growth, DNA repair, and neuropeptide mediated signaling.
Wiemhoefer, A   +29 more
core   +1 more source

Home - About - Disclaimer - Privacy